SIG – Citi rates the stock as Neutral

Following a trading update by Sigma Healthcare, Citi reduces FY22-24 EPS forecasts by -24%, -15% and -2%, respectively and lowers its target price to $0.50 from $0.60. The Neutral rating is unchanged.

Ongoing issues with an enterprise resource planning system, resulting in a significant loss of market share, and covid-related issues were primarily responsible for the earnings downgrades, explains the analyst.

Management downgraded underlying earnings (EBITDA) guidance for FY22 by circa -15%, and now expect a -10% decline over FY21.

Sector: Health Care Equipment & Services.


Target price is $0.50.Current Price is $0.49. Difference: $0.01 – (brackets indicate current price is over target). If SIG meets the Citi target it will return approximately 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).



About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →